Antibodies binding to citrullinated histone 2A and/or 4
AssigneeCitryll B.V.
InventorsJozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi, Johannes Wilhelmus Gerardus Van Rosmalen
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.
Claims13
A polynucleotide encoding an antibody or binding fragment thereof that specifically binds to a citrullinated epitope on deiminated human histone 2A and/or histone 4, wherein the antibody or binding fragment thereof comprises:
- a) a VL CDR1 set forth in SEQ ID NO:
- 9 (QSLLDADGKTY);
- and
- b) a VH CDR1 set forth in SEQ ID NO:
- 1 (GYTFTNYG), a VH CDR2 set forth in SEQ ID NO:
- 2 (INTYSGEA), a VH CDR3 set forth in SEQ ID NO:
- 3 (LRGYTYQS FDEGGDY), a VL CDR2 set forth in SEQ ID NO:
- 4 (LVS) and a VL CDR3 set forth in SEQ ID NO:
- 5 (WQGTHFPYT).
A method of treating a pathology associated with citrullination in a patient comprising administering to the patient a therapeutically effective amount of an antibody or binding fragment thereof that specifically binds to a citrullinated epitope on deiminated human histone 2A and/or histone 4, wherein the antibody or binding fragment thereof comprises:
- a) a VL CDR1 set forth in SEQ ID NO:
- 9 (QSLLDADGKTY);
- and
- b) a VH CDR1 set forth in SEQ ID NO:
- 1 (GYTFTNYG), a VH CDR2 set forth in SEQ ID NO:
- 2 (INTYSGEA), a VH CDR3 set forth in SEQ ID NO:
- 3 (LRGYTYQS FDEGGDY), a VL CDR2 set forth in SEQ ID NO:
- 4 (LVS) and a VL CDR3 set forth in SEQ ID NO:
- 5 (WQGTHFPYT).
Dependencies are inferred from the claim text.